Abstract: Demographic shifts toward an increasingly older population have resulted in a high prevalence of persons taking cardiovascular medication. Many patients on cardiovascular medications will require surgical intervention for conditions often unrelated to their cardiovascular pathology. Cardiologists and anesthesiologists alike must be knowledgeable about the potential interactions between cardiovascular drugs and anesthetics agents or adjuvant therapies administered perioperatively. Current recommendations suggest that beta blockers, calcium channel blockers, amiodarone, and alpha 2 agonists should be continued throughout the perioperative period, whereas angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics should be discontinued on the morning of surgery and resumed in the immediate postoperative period, unless contraindicated.
G eriatric patients not uncommonly are receiving cardiovascular medications for the management of ischemic heart disease and essential hypertension, although the use of these agents is not confined to the elderly population. Indeed, hypertension affects approximately 50 million persons in the United States, 1 and ischemic heart disease, with a prevalence rate of 68 per 1000 persons, affects approximately 18.5 million Americans. As the population continues to age, this prevalence rate will increase further.
Multiple oral antihypertensive drugs are administered alone or in combination to control hypertension. Successful management of hypertension has been demonstrated by cumulative evidence from numerous clinical trials to decrease rates of both cerebrovascular and cardiovascular morbidity and mortality. However, it is important to appreciate that in the absence of concomitant cardiovascular disease or hypertensive end-organ damage (eg, left ventricular ͓LV͔ hypertrophy, renal dysfunction, cerebrovascular disease, congestive heart failure, or coronary artery disease ͓CAD͔), stage I hypertension (systolic blood pressure from 140 to 159 mm Hg or diastolic blood pressure from 90 to 99 mm Hg) does not increase perioperative risk in noncardiac surgery. 2, 3 However, the presence of LV hypertrophy does increase perioperative cardiovascular risk in noncardiac surgery. Indeed, in men with LV hypertrophy and CAD, the risk of perioperative myocardial ischemia in association with major noncardiac surgery is substantially increased. 4 There are also 3 categories of surgical procedures where perioperative cardiovascular risk owing to baseline hypertension alone is notable, and these involve carotid procedures, 5 cardiac surgery, 6 and pheochromocytoma resection. 7 For surgical patients without these conditions, there is negligible additional cardiovascular risk as a result of worsening hypertension secondary to the preoperative discontinuation of antihypertensive drugs. 8 Many patients on cardiovascular medications will require surgical intervention for conditions often unrelated to their cardiovascular pathology. Anesthetic advances have enabled an anesthesiologist to adjust the anesthetic approach to optimally manage patients with cardiovascular disease. To do so, however, a clinician must be knowledgeable about the potential interactions between the cardiovascular agents used by patients and the anesthetic drugs administered in the operating room. Adjustment of an individual patient's antihypertensive regimen may or may not be indicated in hypertensive patients presenting for surgery. The decision to continue or discontinue cardiovascular drugs, especially antihypertensive agents, should be on the basis of an individual risk/benefit analysis preoperatively. This review article will discuss which cardiovascular agents will reduce risk when continued preoperatively and which drugs may actually increase risk if administered on the morning of surgery. Drugs in the former category include beta blockers, alpha-2 agonists, and calcium channel blockers. Those in the latter category include drugs that inhibit the renin-angiotensin system and diuretics.
BETA BLOCKERS
Beta blockers are commonly administered to patients with hypertension and/or ischemic heart disease, who are undergoing surgical procedures. Historically, there had been concern that continuing beta blocker use in the perioperative period could attenuate the physiologic responses to hypovolemia, hypoxia, and hypercarbia. There was also concern that the negative inotropic effects of certain inhalational anesthetics, in combination with the negative inotropic and chronotropic effects of beta blockers, would trigger hemodynamic instability. However, with careful attention being made to avoid excessively high concentrations of inhalation agents and with the development of newer volatile agents with more benign effects on the cardiovascular system, the addition of beta blockade only minimally affects hemodynamic responses. 9 Specifically, sevoflurane and desflurane, the newest inhaled anesthetics, primarily reduce system vascular resistance rather than depress cardiac contractility. One may encounter a limited reduction in LV function and mean arterial blood pressure, but negligible change in heart rate or cardiac output. 10 Indeed, the introduction of esmolol, with its rapid onset and truncated half-life, offered anesthesiologists a valuable adjuvant therapy to treat intraoperative hypertension, tachycardia, and myocardial ischemia. Esmolol given immediately before the induction of anesthesia and laryngoscopy has proven efficacious in blunting untoward hemodynamic responses to endotracheal intubation. 11 We now know that perioperative beta blockade in selected at-risk populations is associated with an impressive cardioprotective effect against myocardial ischemia. Hence, a recent focused guideline on perioperative beta blockade by the American College of Cardiology/American Heart Association recommends that patients on beta blockers should continue to receive them perioperatively.
The evidence for this recommendation was mainly on the basis of the body of literature pertaining to the dangers of beta blocker withdrawal that has been accumulating for more than 3 decades. 13, 14 Not only is perioperative withdrawal of beta blockade associated with myocardial ischemia, but a recent prospective cohort study also showed that the risk of myocardial infarction (MI) increased substantially by withdrawal of cardioselective beta blockade. 15 The reasons for developing beta blocker withdrawal complications, which typically begins 72 hours after cessation of the drugs, include heightened sensitization to endogenous catecholamines, resulting in an increase in sympathetic nervous system activity. 16 Additional concomitants include progression of the underlying disease, increased platelet aggregation, shifts in the oxygen-hemoglobin dissociation curve, rebound elevation of plasma renin activity, and changes in thyroid hormone metabolism.
In recent years, there has been considerable debate about the relative merits of initiating beta blocker therapy preoperatively in patients having major surgery who were not previously on beta blockers. The results of the recent Perioperative Ischemic Evaluation Study, however, have cast doubt on the wisdom of administering beta blockers prophylactically. 17 Specifically, this prospective, multicenter, randomized, placebo-controlled trial sought to determine the effects of perioperative beta blockers versus placebo. The investigators studied 8351 patients aged Ն45 years, with or at risk for atherosclerotic disease, who were undergoing noncardiac surgery. The patients were assigned by computerized phone randomization to either extended-release metoprolol or placebo. Participants received extended-release metoprolol 100 mg or placebo 2 to 4 hours before surgery. The first postoperative dose (100 mg or placebo) was given 6 hours after surgery or sooner if the heart rate was Ն80 bpm or systolic blood pressure was Ն100 mm Hg. The patients then started oral extended-release metoprolol 200 mg or placebo 12 hours after the first postoperative dose and continued the medication daily for 30 days. The investigators reported that in patients undergoing noncardiac surgery, prophylactic beta blockade substantially reduced the risk of nonfatal MI but increased the incidence of death and stroke. Post hoc multivariate analyses suggested that clinically significant hypotension, bradycardia, and stroke caused the increase in death in the metoprolol group. Importantly, it has been widely suggested that these findings may be related to the relatively high and untitrated doses of metoprolol administered in the Perioperative Ischemic Evaluation study.
In summary, existing beta-blocker therapy in patients with a history of hypertension or ischemic heart disease should be continued up to and including the day of surgery and throughout the entire perioperative period. The role of prophylactic beta blocker therapy has been called into question.
CALCIUM CHANNEL BLOCKERS
Calcium channel blockers are widely used for a variety of conditions, including hypertension, myocardial ischemia, cardiac arrhythmias, pulmonary hypertension, cerebral vasospasm, and esophageal spasm. Calcium channel blockers are potentially dangerous in the perioperative venue owing to their primary vasoactive and cardiac effects that include a reduction in systemic vascular resistance, as well as negative inotropic and chronotropic effects. These properties are also seen with several general anesthetic agents, so it is not surprising that initial questions were raised about the potential for additive, or even synergistic effects when calcium channel blockers were administered to patients having potent inhalational anesthetic drugs. Despite their documented pharmacologic effects, there is no evidence that chronic administration of calcium channel blockers appreciably augments a patient's risk for anesthesia-related complications in the absence of other contributing factors. 18, 19 Thus, when patients with preserved ventricular function receive preoperative calcium channel blockers, the contemporaneous use of moderate concentrations of inhalation agents is well tolerated. However, the anesthesiologist must also be aware that calcium channel blockers can potentiate the paralysis produced by neuromuscular blocking drugs. In addition, they can potentiate effects of theophylline and increase digoxin levels. Anesthesiologists must also be cognizant that cimetidine and ranitidine increase the bioavailability of calcium channel blockers, and barbiturates reduce their bioavailability. An area of grave concern is the dangerous interaction between the use of dantrolene to treat malignant hyperthermia and the administration of verapamil. Dantrolene, a hydantoin derivative, is the only drug that is efficacious in treating an acute episode of malignant hyperthermia, a potentially lethal hypermetabolic disorder of skeletal muscle that is triggered by inhaled volatile anesthetics, or by the depolarizing muscle relaxant, succinylcholine. Dantrolene is thought to act by reducing calcium release from the sarcoplasmic reticulum, effectively abolishing excitation-contraction coupling in muscle cells and reducing intracellular calcium levels. Verapamil has the ability to decrease calcium influx and can interact with dantrolene to produce hyperkalemia and critically serious myocardial depression. 20 A theoretical concern is the potential for heart block in patients chronically treated with calcium channel blockers who are having general anesthesia. This concern is on the basis of wellknown ability of calcium channel blockers to slow the sinoatrial and atrioventricular nodes and to prolong atrioventricular conductivity. Henling et al 21 examined the frequency of heart block in 188 patients having coronary artery bypass grafting. Patients were divided into 4 groups: those receiving (1) chronic calcium channel blockers, (2) beta blockers, (3) chronic calcium channel blockers and beta blockers, and (4) neither calcium channel blockers nor beta blockers (controls). Diltiazem, nifedipine, and verapamil were the calcium channel blockers used in this study. The investigators reported no difference among all groups in the frequency of firstdegree heart block, and concluded that continuation of calcium channel blockers, even concurrently with beta blockers, did not produce cardiac conduction abnormalities. Moreover, a recent metaanalysis of Ͼ1000 patients included in 11 studies showed that perioperative calcium channel blockers, particularly diltiazem, substantially reduced myocardial ischemia (relative risk ͓RR͔: 0.49; 95% confidence interval ͓CI͔: 0.30 -0.80), supraventricular tachycardia (RR: 0.52; 95% CI: 0.37-0.72), and major morbidity and mortality (RR: 0.35; 95% CI: 0.15-0.86). 22 On the basis of lack of notable hemodynamic consequences encountered with induction and maintenance of general anesthesia, coupled with the potential salutary effects on coronary vasospasm, hypertension, and supraventricular tachycardia, the continuation of calcium channel blockers throughout the perioperative period is recommended in patients with normal or slightly impaired cardiac function. 23 Caution should be exercised, however, for patients with a LV ejection fraction of Ͻ40%. Finally, it should be noted that, unlike the situation with beta blockers, there are no documented withdrawal symptoms associated with perioperative discontinuation of calcium channel blockade.
AMIODARONE
Amiodarone has been proven effective for the treatment of refractory ventricular and supraventricular arrhythmias. This powerful antiarrhythmic and coronary vasodilator, however, is associated with some important drug interactions, and in this context it must be appreciated that the elimination half-life of amiodarone is quite protracted, approaching 2 months. The drug has been shown to increase serum levels of digoxin, fentanyl, quinidine, procainamide,
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Cardiovascular Pharmacotherapeutic Considerations phenytoin, and theophylline. Amiodarone also potentiates the anticoagulant properties of warfarin compounds, as well as the bradycardia seen with beta blockers and calcium channel blockers. Further, the drug has been implicated in the development of pulmonary alveolitis/interstitial pneumonitis and mild hepatic injury, as well as thyroid dysfunction. The perioperative use of amiodarone was initially considered quite controversial. Adverse effects, such as negative inotropic effects, peripheral vasodilation, and dose-related negative chronotropic effects were reported in conjunction with the administration of general anesthesia. Of marked concern was the suggestion that usual therapies, such as atropine or alpha-adrenergic-receptor agonists, were ineffective in treating these complications. 24, 25 More recent data, however, suggest that amiodarone is safe for use during general anesthesia for both cardiac and noncardiac surgical procedures. 26, 27 This is fortuitous since, given the pharmacokinetics of the drug, it would be unreasonable to discontinue therapy for an extended period in patients with life-threatening arrhythmias. Moreover, amiodarone has found a niche in the intraand postoperative treatment of coronary artery bypass graft patients who develop atrial fibrillation.
ALPHA 2 AGONISTS
Alpha 2 agonists, such as the antihypertensive agent clonidine, are thought to stimulate alpha 2 receptors in the vasomotor center of the medulla oblongata to reduce sympathetic nervous system activity and enhance vagal tone. The most widely studied alpha 2 agonists are clonidine, mivazerol (unavailable in the United States), and dexmedetomidine. A partial agonist with an alpha 2 to alpha 1 selectivity of 39:1, clonidine has the advantage of being available in oral, transdermal, and parenteral forms. Its half-life is approximately 20 hours. Dexmedetomidine is a much shorter-acting intravenous alpha 2 agonist with a selectivity ratio of 1300:1, and is typically used for sedation rather than for its antihypertensive effect. In addition to its antihypertensive action, clonidine has been shown to reduce the anesthetic requirement (by Ն40%) for volatile drugs or opioids and to provide central analgesia and anxiolysis. Clonidine purportedly also has a beneficial antishivering effect. Abrupt withdrawal of clonidine may result in rebound hypertension, typically noted about 18 hours after discontinuation of the drug. Thus, it is important to maintain therapy with this drug until the time of surgery to prevent serious rebound hypertension.
Owing to the ability of alpha 2 agonists to modulate sympathetic tone, it is tempting to speculate that these agents might offer perioperative myocardial protection. It is important to appreciate, however, that many studies evaluating the hemodynamic stabilizing properties of alpha 2 agonists used myocardial ischemia as a surrogate marker for MI and cardiac death. Indeed, most of the investigations conducted to date have not linked the use of perioperative alpha 2 agonists to reduced rates of MI and death. 28 -30 In 1999, Oliver et al 31 conducted a large double-blind, randomized, placebo-controlled study of 2854 patients with known CAD, or with risk factors for CAD, who were given an infusion of mivazerol for 72 hours or placebo. On subgroup analysis, those with known CAD who received mivazerol had fewer cardiac deaths (P ϭ 0.037). However, the rates of MI and all-cause deaths were not different between the mivazerol and placebo groups. In the subgroup of patients having vascular surgery, mivazerol offered substantial myocardial protection. The cardiac death rate was 6% versus 18% with placebo (P ϭ 0.009), and the combined cardiac death rate and MI rate was 10% versus 14% (P ϭ 0.02). MI rate alone, however, was not different between the 2 groups. Therefore, the group who most benefited from mivazerol were those patients with known CAD having vascular surgery.
In 2004, Wallace et al 32 published the results of a prospective, double-blind, randomized trial of 190 patients at risk for CAD scheduled for noncardiac surgery. The patients in the clonidine group (n ϭ 125) received 0.2 mg orally the night before and 1 hour before surgery. A transdermal clonidine patch (0.2 mg/d) was also placed the night before surgery until the fourth postoperative day. The incidence of myocardial ischemia was less on days 0 to 3 compared with the placebo group (14% vs. 31%, P Ͻ 0.01). Long-term follow-up disclosed that the clonidine group had a lower mortality rate at 30 days and at 2 years. Therefore, the investigators concluded that perioperative clonidine reduced ischemic episodes, as well as the long-term incidence of MI and death. However, this apparent benefit lost statistical significance after isolating all patients who received perioperative beta blockers.
To date, there have been no published large randomized controlled trials exploring the infusion of dexmedetomidine to decrease perioperative cardiac morbidity and mortality rates in noncardiac surgery patients.
To summarize, based on somewhat limited evidence, alpha 2 agonists may have a protective role in preventing perioperative morbidity and mortality in patients with known or suspected CAD, especially if they are scheduled for vascular surgery. However, more prospective, large-scale investigations of alpha 2 agonists are needed to assess not merely the surrogate marker of myocardial ischemia but to better elucidate the role of these drugs in the prevention of perioperative cardiac morbidity and mortality.
With regard to hypertensive patients chronically on alpha 2 agonists such as clonidine, perioperative discontinuation of this drug class is dangerous because it is associated with delirium, rebound hypertension, and myocardial ischemia.
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ANGIOTENSIN SYSTEM INHIBITORS
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used primarily in the treatment of hypertension and congestive heart failure, although they are also sometimes given to patients with renal disease or systemic sclerosis.
ACE inhibitors or ARBs may produce notable intraoperative hypotension if administered until the time of surgery. Nonetheless, when first introduced, these agents were considered similar to other classes of antihypertensives and were traditionally continued until the time of surgery. They have since been shown to exacerbate the hypotensive effects of anesthetics. It must be acknowledged, however, that data on the use of ACE inhibitors and ARBs are somewhat conflicting.
More than 15 years ago, Coriat et al 34 studied the effect of continuing chronic ACE inhibitor therapy until surgery. Fifty-one patients were randomized to receive (21 patients) or suspend (30 patients) their respective therapies. Sixteen patients (76%) taking ACE inhibitors before surgery had a systolic blood pressure Ͻ90 mm Hg and required vasopressors, compared with only 6 (20%) of those who discontinued their drug. In sharp contradistinction, a similar study conducted more than a decade ago of 40 patients undergoing cardiac surgery identified no difference between the groups (20 continued ACE inhibitors and 20 did not) in the frequency of intraoperative hypotension. 35 Importantly, however, the group that suspended ACE inhibition experienced a marked increase in blood pressure postoperatively that necessitated the administration of vasodilators.
Brabant et al 36 reported a substantially higher rate of hypotension in vascular surgery patients during the induction of anesthesia associated with ARBs than with ACE inhibitors, beta-blockers, or calcium channel blockers. In addition, the hypotension was more often refractory to treatment with conventional vasopressors such as ephedrine and phenylephrine. It did, however, respond to the ad-ministration of terlipressin, a vasopressin system agonist. This finding is not surprising, given that anesthetics reduce the sympathetic nervous system support of vascular tone, and the reninangiotensin-aldosterone system is blocked by ACE inhibitors and ARBs. Hence, the vasopressin system is the last line of defense against hypotension.
In 2001, Bertrand et al 37 published a prospective, randomized assessment of the hemodynamic responses of 37 patients on chronic ARB therapy having vascular surgery. Eighteen patients had their ARB therapy suspended the day before surgery, whereas 19 patients received their ARB dose 1 hour before anesthetic induction. The latter group had substantially lower systolic blood pressures 5, 15, and 23 minutes after induction. These decreases were associated with more frequent episodes of hypotension, a longer duration of hypotensive episodes, and an increased need for vasoactive drugs. The investigators further stated that they believed recommendations to discontinue ARBs on the day before surgery might be justified.
In 2005, Comfere et al 38 from Mayo Clinic retrospectively studied the relationship between the timing of discontinuing chronic ACE inhibition and ARBs and the development of hypotension in a group of 267 hypertensive patients undergoing elective noncardiac surgery. They determined that patients who took their last ACE inhibitor or ARB therapy Ͻ10 hours before surgery more frequently had moderate hypotension (systolic blood pressure Յ85 mm Hg) during the first 30 minutes after anesthetic induction than those who stopped the dose Ն10 hours before induction (P ϭ 0.02). However, there were no differences between the groups in the incidence of severe hypotension (systolic blood pressure Յ65 mm Hg), nor was there a difference in the need for vasopressors. During the 31 to 60 minutes after induction, the incidence of either moderate or severe hypotension was similar in the 2 groups, as was the incidence of postoperative complications. They concluded that suspension of ACE inhibitor or ARB therapy at least 10 hours before anesthesia was associated with a decreased risk of immediate postinduction hypotension. Clearly, however, it is important to maintain intravascular volume during the perioperative period for patients on these medications.
On the basis of cumulative evidence, it is currently recommended that angiotensin blockade in hypertensive surgical patients be discontinued on the morning of surgery. That said, areas of uncertainty should be explored. It remains to be determined, for example, whether modification of the induction technique could ameliorate the hypotension associated with ACE inhibitors or ARBs. A recent study identified a reduction in hypotension associated with etomidate administration in this setting, rather than using the highly vagotonic agent propofol that perhaps confounds the observed hypotension with the hypotensive effects associated with propofolinduced bradycardia. 39 In addition, propofol causes a marked reduction in systemic vascular resistance, which in these circumstances is already decreased by inhibition of the renin-angiotensin-aldosterone system.
DIURETICS
Diuretics are often prescribed for patients with hypertension and/or congestive heart failure. In chronic hypertensive patients treated with diuretics, intravascular volume contraction may exist, rendering these patients more prone to hypotension associated with induction of anesthesia. Hypokalemia (defined as serum potassium Ͻ3.5 mEq/L) is also common in hypertensive patients managed with chronic diuretic therapy. With the exception of the competitive aldosterone antagonists (spironolactone and eplerenone), all other classes of diuretics cause hypokalemia. Serum potassium Ͻ3.5 mEq/L has been reported in 15% of patients, and levels Ͻ3.0 mEq/L have been detected in 10% of diuretic-treated patients. 40 Although chronic diuretic-induced hypokalemia is less arrhythmogenic than acute hypokalemia, nonetheless serum potassium levels Ͻ3.0 are associated with a 2-fold greater incidence of ventricular arrhythmias than levels Ͼ3.0 mEq/L. 40 Hypokalemia can be especially problematic in the setting of cardiac surgery. In a prospective multicenter trial of 2402 patients having cardiac surgery, a serum potassium Ͻ3.5 mEq/L predicted serious arrhythmia (RR: 2.2; 95% CI: 1.2-4), intraoperative arrhythmia (RR: 2.0; 95% CI: 1.0 -3.6), and postoperative atrial flutter/fibrillation (RR: 1.7; 95% CI: 1.0 -2.7). 41 Digitalis toxicity is enhanced in the setting of hypokalemia, and it is important to appreciate that intraoperative hyperventilation will further exacerbate hypokalemia. For each 10 mm Hg reduction in arterial carbon dioxide tension, an additional 0.5 mEq/L decrease in serum potassium will be imposed. Depending on the type of diuretic administered, other electrolyte imbalances can occur, including hyponatremia, hypochloremia, hypomagnesemia, hypercalcemia, and metabolic alkalosis. Thiazide diuretics have been linked to glucose intolerance, which may be an effect of hypokalemia rather than the diuretic itself. 42 The potassium-sparing diuretics may be associated with occasional hyperkalemia and metabolic acidosis. Because electrolyte imbalance and acid-base disorders can affect the action of neuromuscular blocking drugs, anesthesiologists check preoperative potassium levels and use neuromuscular blockade monitors intraoperatively to evaluate the degree of muscle paralysis in order to titrate these agents appropriately for optimal surgical conditions.
For all of the reasons outlined previously, diuretics are usually discontinued on the morning of surgery. An additional, practical reason also is contributory to the recommendation to suspend diuretics preoperatively. With the rapid expansion of sophisticated diagnostic tools and minimally invasive surgery, many patients do not receive general anesthesia for their diagnostic studies or operations. Rather, they receive monitored anesthesia care, rendering them sedated but not unconscious. Hence, the urge to void during a procedure could prove very distressing for many patients, and this unpleasant situation is obviated by withholding diuretics preoperatively.
SUMMARY
It is critical to perform an individual risk-benefit analysis on every patient undergoing general anesthesia. The following recommendations (Table 1 ) emphasized in this article generally apply to the perioperative management of patients taking cardiovascular medications. 
